DUBLIN--(BUSINESS WIRE)--The "Vaccine Adjuvants Market - Growth, Trends, and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
The propelling factors for the growth of the vaccine adjuvants market include the unmet needs for vaccines against certain diseases, expanding government recommendations for immunizations, technological innovations, and increasing use of recombinant subunit and synthetic vaccines.
Across the world, various governmental organizations are promoting and raising awareness regarding immunization against various diseases, like anthrax, BCG, hepatitis, HPV, influenza, varicella, smallpox, and other conditions. Thus, increasing the risk of infectious diseases, the effectiveness of vaccines, enhanced immunogenicity, and various government initiatives are likely to enhance the demand over the forecast period.
The adjuvant market is gaining a boost from the increasing use of recombinant subunit vaccines. As usage is increasing, the demand for various adjuvants is expanding. Over the coming years, more developments are expected to take place, increasing the need for adjuvants. The market is also expected to grow with a moderate rate, primarily fuelled by the increasing adoption of biologics and biosimilars and rising R&D in vaccines across the world.
Toxicity is the single-most crucial impediment while introducing most of the adjuvants for human use. Toxicity may also increase the financial burden on market players during the development and manufacturing phases. Thus, the negative impacts of toxicity of adjuvants on vaccine manufacturing cost and safety profiles of vaccines are hindering the growth of the market.
Key Market Trends
Carbohydrates adjuvants is the segment under type that is expected to grow the fastest during the forecast period
Carbohydrates are easily metabolized and generate very less toxic metabolites or long-lasting tissue deposits. Due to these advantageous reasons, their acceptance and adoption have increased since its introduction in the market. Carbohydrate adjuvants with other new types have an additional role of signaling the immune system. They boost the immune response and enhance immunogenicity.
There have also been several recent developments made in the treatment of hepatitis C virus using direct acting antivirals, which has helped researchers to shorten treatment durations and minimal side effects for patients infected with HCV. A large number of research potential and possibilities are expected over the forecast period, which may be useful for better treatment of infectious diseases and cancer treatment. Thus, the growth rate is expected to be high for this type of vaccine adjuvant.
Asia-Pacific holds the fastest growth and is expected to follow the same trend over the forecast period
Asia-Pacific is expected to witness a significant growth, due to the presence of a large population prone to various chronic and infectious diseases, such as HIV, influenza, hepatitis, and cancer. Therefore, the introduction of innovative vaccine adjuvants provides better solutions to patients at marginally lower costs. The market is growing at a significant rate, owing to the development of innovative and efficient products to meet the increasing demand from end users.
Competitive Landscape
The major companies have conducted product launches, approvals, acquisitions, and collaborations for the development of novel vaccine adjuvants, thereby, building a competitive landscape in the market. Major players are engaged in the discovery and development of new adjuvants to treat fatal diseases. In the coming years few other players are expected to enter into the market. In the coming years few other players are expected to enter into the market.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expanding Government Recommendations for Immunizations
4.2.2 Unmet Vaccine Market Needs for Certain Diseases
4.2.3 Increasing Use of Recombinant Subunit and Synthetic Vaccines
4.3 Market Restraints
4.3.1 Side Effects and High Toxicity of Adjuvants
4.3.2 High R&D Cost of Developing a New Adjuvant
4.4 Porter's Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Mineral Salt-based Adjuvant
5.1.2 Tensoactive Adjuvants
5.1.3 Adjuvant Emulsions
5.1.4 Liposome Adjuvants
5.1.5 Carbohydrate Adjuvants
5.1.6 Bacteria-derived Adjuvants
5.1.7 Virus-like Particles (VLP)
5.1.8 Other Types
5.2 By Route of Administration
5.2.1 Active Immunostimulants
5.2.2 Carriers
5.2.3 Vehicle Adjuvants
5.3 Geography
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Adjuvatis
6.1.2 Brenntag AG
6.1.3 Chemtrade Logistics
6.1.4 GlaxoSmithKline Plc
6.1.5 Invivogen
6.1.6 Merck KGaA
6.1.7 Novavax Inc
6.1.8 Oz Biosciences
6.1.9 Seppic (Air Liquide)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/lsvmpx
